Clinical trials: Treated Hypertension
Idiopathic Intracranial Hypertension
Venous Sinus Stenting With the River Stent in IIH
The objective of the study is to show that stenting the transverse-sigmoid sinus with the River stent is safe and has probable benefit to relieve clinical symptoms in subjects with idiopathic intracranial hypertension (IIH).
- Trial name
- NCT03556085
- Testing
- Venous sinus stenting (Serenity River)
- Where
- 6 sites in United States
- Volunteers
- 39 people
- Sponsor
- Serenity Medical, Inc.
Portal Hypertension
Clinical Study of PTFE Covered Stent for Treating Portal Hypertension
To validate the safety and efficacy of TIPS (Transjugular Intrahepatic Portosystemic Shunt) using PTFE covered stent in the treatment of portal hypertension.
- Trial name
- NCT06117735
- Testing
- Transjugular Intrahepatic Portosystemic shunt
- Where
- 4 sites in China
- Volunteers
- 177 people
- Sponsor
- Enlight Medical Technologies (Shanghai) Co., Ltd
Glaucoma, Ocular Hypertension
Preservative-Free Tafluprost (MK-2452) for the Treatment of Open-Angle Glaucoma or Ocular Hypertension (MK-2452-002)
This study will test the hypothesis that preservative-free tafluprost (MK-2452) is non-inferior to preservative-free timolol maleate with respect to the diurnal intraocular pressure (IOP) change from baseline after 4 weeks of…
- Trial name
- NCT01254604
- Testing
- Preservative-Free Tafluprost or vehicle, Preservative-Free Timolol maleate
- Volunteers
- 190 people
- Sponsor
- Merck Sharp & Dohme LLC
Hypertension
Efficacy and Safety of Valsartan/Hydrochlorothiazide Combination Therapy in Patients With Hypertension
This is a double-blind study to evaluate the reduction in systolic blood pressure using a therapy initiated with valsartan 160 mg or valsartan + hydrochlorothiazide (HCTZ) 160/12.5 mg compared to a more conventional approach…
- Trial name
- NCT00280540
- Testing
- Valsartan/Hydrochlorothiazide
- Where
- United States
- Volunteers
- 648 people
- Sponsor
- Novartis
Essential Hypertension
A Study for PMS of AZL-M/CLD FDC in the Treatment of Participants With Essential HTN in South Korea
The purpose of this study is to evaluate the safety by assessing all serious and non-serious adverse events (AEs), irrespective of relatedness or expectedness, as well as other safety parameters including laboratory values…
- Trial name
- NCT04470830
- Where
- South Korea
- Volunteers
- 718 people
- Sponsor
- Celltrion Pharm, Inc.
Hypertension, Vascular Diseases
Streamlined Denervation With spYral For an Optimized Treatment (SPYRAL SWYFT) in Subjects With Uncontrolled Hypertension
The purpose of the SPYRAL SWYFT sub-study is to evaluate whether renal denervation with the Symplicity Spyral system performed in the main and first order branch renal arteries yields a shorter procedure time and is as effective…
- Conditions
- Hypertension, Vascular Diseases, Cardiovascular Diseases, Chronic Kidney Diseases
- Trial name
- SWYFT (NCT07115953)
- Testing
- Symplicity Spyral™ multi-electrode renal denervation system
- Where
- 21 sites in Australia, Belgium and 7 more
- Volunteers
- 130 people
- Sponsor
- Medtronic Vascular
Essential Hypertension
Efficacy and Safety of Once Daily Dosing of Aliskiren (300 mg (qd) Once a Day) to Twice Daily Dosing of Aliskiren (150 mg (Bid) Twice a Day) in Treating Moderate Hypertension.
This study will compare the safety and efficacy of once daily dosing of aliskiren to twice daily dosing of aliskiren in patients with moderate hypertension
- Trial name
- NCT00654875
- Testing
- Aliskiren
- Where
- 3 sites in United States, Germany and 1 more
- Volunteers
- 328 people
- Sponsor
- Novartis
Diabetes Mellitus
Comparison of Pharmacodynamic Effects of Sotagliflozin and Empagliflozin in T2DM Patients With Mild to Moderate Hypertension
Primary Objective: To compare the metabolic and gastrointestinal pharmacodynamic (PD) effects of an 8 weeks treatment with sotagliflozin once daily (QD) to an 8 weeks treatment to empagliflozin QD in mild or moderate hypertensive…
- Trial name
- NCT03462069
- Testing
- Sotagliflozin (SAR439954), Empagliflozin
- Where
- Germany
- Volunteers
- 41 people
- Sponsor
- Sanofi
Glaucoma
VividWhite Glaucoma Implant (VW-51) Pivotal Study
The VividWhite Glaucoma Implant (VW-51) is a novel surgical implant designed to treat glaucoma. This study is a 12-month, 65-participant non-comparative multicentre study to assess the safety and effectiveness of the VW-51…
- Trial name
- NCT06176170
- Testing
- VividWhite Glaucoma Implant (VW-51)
- Where
- 6 sites in Australia
- Volunteers
- 65 people
- Sponsor
- VividWhite Pty Ltd
Hypertension
A Dose Finding Study of IBI3016 in Mild to Moderate Hypertensive Patients
The purpose of this study is to evaluate the efficacy, safety and tolerability of IBI3016 or placebo, given subcutaneously, every 3 or 6 months, at different dose levels in patients with mild to moderate hypertension
- Trial name
- NCT07352969
- Testing
- IBI3016
- Where
- China
- Volunteers
- 352 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Ocular Hypertension, Primary Open Angle Glaucoma
Glaucoma Adherence Study
The purpose of this study is evaluate adherence to DuoTrav® when reinforced by the use of the Travalert™ Dosing Aid.
- Trial name
- GAS (NCT00676637)
- Testing
- Travoprost 0.004%/timolol 0.05% fixed combination eye drops (DuoTrav), Travalert Dosing Aid
- Where
- 4 sites in France, Italy and 2 more
- Volunteers
- 55 people
- Sponsor
- Alcon Research
Hypertension
Xirtam H Combination In the Treatment of Hypertension Evaluation Study.
This is post-marketing observational study in which data on safety and effectiveness of Xirtam H will be collected from routine clinical practice.
- Trial name
- XCITE (NCT01219556)
- Testing
- Olmesartan plus hydrochlorothiazide (Xirtam H, BAY98-7105)
- Where
- India
- Volunteers
- 8,704 people
- Sponsor
- Bayer
Hypertension
Clevidipine in the Treatment of Patients With Severe Hypertension (VELOCITY)
The purpose of this study was to determine the safety of clevidipine for treating severely elevated blood pressure, defined as systolic (SBP) >180 mmHg and/or diastolic blood pressure (DBP) >115 mmHg assessed on 2 successive…
- Trial name
- VELOCITY (NCT00369837)
- Testing
- clevidipine
- Where
- 14 sites in United States
- Volunteers
- 131 people
- Sponsor
- The Medicines Company
Hypertension
Additional Effect of A Life Style Program on Antihypertensive Treatment With Telmisartan
This post-marketing surveillance study is designed to supplement the data on efficacy and tolerability of Micardis® and MicardisPlus® in patients at cardiovascular risk under general practice conditions.
- Trial name
- NCT01108796
- Where
- 182 sites in Slovenia
- Volunteers
- 1,856 people
- Sponsor
- Boehringer Ingelheim
Essential Hypertension
Efficacy and Safety of Valsartan and Amlodipine in Patients With Essential Hypertension
The purpose of this study is to evaluate the safety and efficacy of fixed combination of valsartan (40 mg and 80 mg) and amlodipine (2.5 mg and 5 mg), valsartan and amlodipine alone, and placebo in reducing blood pressure.
- Trial name
- NCT00425373
- Testing
- Valsartan + amlodipine 40/2.5 mg, Valsartan + amlodipine 40/5 mg, Valsartan + amlodipine 80/2.5 mg
- Where
- Japan
- Volunteers
- 1,474 people
- Sponsor
- Novartis Pharmaceuticals
Normal Tension Glaucoma (NTG), Low-Tension Glaucoma, Bilateral
Study of an Investigational Product, QLS-111, Provided as an Eyedrop, for Treatment of Normal Tension Glaucoma (NTG)
Qlaris' Phase 2 clinical trial investigating the safety, tolerability, and ocular hypotensive efficacy of QLS-111 in normal tension glaucoma patients.
- Conditions
- Normal Tension Glaucoma (NTG), Low-Tension Glaucoma, Bilateral, Low-Tension Glaucoma, Unspecified Eye, Glaucoma
- Trial name
- Nightingale (NCT06030193)
- Testing
- QLS-111 ophthalmic solution (0.015%), Timolol Maleate PF 0.5% Ophthalmic Solution (Timolol)
- Where
- South Korea
- Volunteers
- 37 people
- Sponsor
- Qlaris Bio, Inc.
Hypertension
Clinical Characteristics and Medication Satisfaction of Kanarb Tablet in Korean Hypertensive Patient(Kanarb-Hypertension Epidemiology Medication Satisfaction Study)
1. Investigate the clinical characteristics, medication satisfaction and quality of life of anti-hypertensive drugs in Korean hypertensive patients 2.
- Trial name
- K-HEMS (NCT02394392)
- Where
- South Korea
- Volunteers
- 12,691 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Essential Hypertension
A Study to Evaluate the Efficacy and Safety of Co-administration of AD-227A and AD-227B
The purpose of this study is to evaluate the efficacy and safety of co-administration of AD-227A and AD-227B in patients with essential hypertension
- Trial name
- NCT06441630
- Testing
- AD-227A, AD-227B, AD-227C
- Where
- South Korea
- Volunteers
- 251 people
- Sponsor
- Addpharma Inc.
Hypertension
Crossover Bioequivalence Study of Irbesartan 300 mg Tablets Under Fed Conditions
The objective of this study was to prove the bioequivalence of Roxane Laboratories' Irbesartan 300 mg Tablets under fed conditions.
- Trial name
- NCT01712100
- Testing
- Irbesartan, Avapro
- Where
- United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Roxane Laboratories
Glaucoma, Open-Angle
Safety and Efficacy of Bimatoprost/Timolol Fixed Combination Versus Latanoprost in Patients With Open-Angle Glaucoma Who Have Never Been Treated
This study will evaluate the safety and efficacy of bimatoprost/timolol fixed combination (GANfort®) versus latanoprost (Xalatan®) in patients with open-angle glaucoma who have never been previously treated and are at high risk…
- Trial name
- NCT01243567
- Testing
- bimatoprost 0.03%/timolol 0.5% combination ophthalmic solution, latanoprost 0.005% ophthalmic solution
- Where
- 2 sites in Portugal, Spain
- Volunteers
- 81 people
- Sponsor
- Allergan